lapatinib + capecitabine
Проводит Новартис Фарма АГ
Страница компанииAn Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00338247/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- Плановая дата окончания (03.2015) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Биомаркеры в критерияхHER2
- Опухольнужен измеримый очаг (RECIST)
- Стадияметастатическая (IV), местно-распространённая (III)
- Ожидаемая продолжительность жизнине меньше 8 нед.
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 11 · невключение: 10
Критерии включения
- May have received prior lapatinib in another trial. Previous capecitabine (as previous agent or non-lapatinib containing regimen) is also permitted.
- Prior treatment with hormonal therapy is allowed.
- Must have advanced or metastatic breast cancer with progression (as assessed by modified RECIST) after prior therapy, which must include all of the following: prior treatment with an anthracycline, a taxane, and trastuzumab alone or in combination with other therapy. Trastuzumab must have been administered in the adjuvant, or locally advanced or metastatic setting.
- Must have tumors that overexpress ErbB2 defined as +3 by IHC or FISH positive for ErbB2 gene amplification. The status of ErbB2 expression must be documented prior to study entry.
- Must be >/= 18 years of age
- Life expectancy of > 8 weeks
- Must have recovered from side effects of previous treatment
- Patients with CNS mets are eligible provided treatment with prohibited medications as listed in the protocol are not required
- Cardiac ejection fraction must be within the institutional range of normal as measured by ECHO. MUGA scans are allowed if ECHOs cannot be performed
- Able to swallow and retain oral medications
- Must have adequate hematologic, hepatic and renal function
Критерии невключения
- Pregnant or lactating females
- Malabsorption syndrome, disease significantly affecting GI function, or resection of the stomach or bowel, or ulcerative colitis
- Concurrent disease or condition that would make the patient inappropriate for study participation
- Unresolved or unstable toxicity from prior administration of another investigational drug and/or prior cancer treatment
- Uncontrolled infection
- Active cardiac disease defined as history of uncontrolled or symptomatic angina; history of arrhythmias requiring medication, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation; MI < 6 months from study entry; uncontrolled or symptomatic CHF; ejection fraction below the institutional normal limit; any other cardiac condition that would make this protocol unreasonably hazardous for the patient
- Receiving concurrent chemotherapy (other than capecitabine), radiation therapy, immunotherapy, biologic therapy or hormonal therapy for cancer. Concurrent therapy with bisphosphonates is allowed
- History of allergic reaction attributed to compounds of similar composition to lapatinib or any excipients
- History of allergic reactions attributed to compounds of similar chemical composition to capecitabine, fluorouracil or excipients
- Known DPD deficiency
Источник: ClinicalTrials.gov, NCT00338247 · запись обновлена в реестре 6 апреля 2016.
Дизайн и результаты
Цель исследования
This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00338247 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, сроки, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.